- Home
- UFCS vs GHRS Comparison
UFCS vs GHRS Comparison
Compare UFCS & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- GHRS
- Stock Information
- Founded
- UFCS 1946
- GHRS 2018
- Country
- UFCS United States
- GHRS Ireland
- Employees
- UFCS N/A
- GHRS N/A
- Industry
- UFCS Property-Casualty Insurers
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- UFCS Finance
- GHRS Health Care
- Exchange
- UFCS Nasdaq
- GHRS Nasdaq
- Market Cap
- UFCS 765.5M
- GHRS 774.1M
- IPO Year
- UFCS N/A
- GHRS 2021
- Fundamental
- Price
- UFCS $30.93
- GHRS $13.04
- Analyst Decision
- UFCS Buy
- GHRS Strong Buy
- Analyst Count
- UFCS 2
- GHRS 8
- Target Price
- UFCS $30.50
- GHRS $30.63
- AVG Volume (30 Days)
- UFCS 120.7K
- GHRS 303.4K
- Earning Date
- UFCS 11-04-2025
- GHRS 11-13-2025
- Dividend Yield
- UFCS 2.05%
- GHRS N/A
- EPS Growth
- UFCS 143.32
- GHRS N/A
- EPS
- UFCS 3.51
- GHRS N/A
- Revenue
- UFCS $1,322,727,000.00
- GHRS N/A
- Revenue This Year
- UFCS $12.34
- GHRS N/A
- Revenue Next Year
- UFCS $14.56
- GHRS N/A
- P/E Ratio
- UFCS $8.92
- GHRS N/A
- Revenue Growth
- UFCS 14.18
- GHRS N/A
- 52 Week Low
- UFCS $19.19
- GHRS $6.00
- 52 Week High
- UFCS $32.58
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- UFCS 52.30
- GHRS 45.13
- Support Level
- UFCS $29.75
- GHRS $12.67
- Resistance Level
- UFCS $31.65
- GHRS $14.96
- Average True Range (ATR)
- UFCS 0.68
- GHRS 0.75
- MACD
- UFCS -0.09
- GHRS -0.07
- Stochastic Oscillator
- UFCS 40.28
- GHRS 17.21
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.